CoChat
Sign Up
Cited by 484Chronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseasesTransplantation: Methods and Outcomes

The DOI matches its Crossref record; 56 of the 59 references it cites were found in a registry or an index.

An Immune Basis for Lung Parenchymal Destruction in Chronic Obstructive Pulmonary Disease and Emphysema

Open access
Grumelli, Sandra, Corry, David B, Song, Li-Zhen, Song, Ling, Green, Linda, Huh, Joseph, Hacken, Joan, Espada, Rafael, Bag, Remzi, Lewis, Dorothy E, Kheradmand, Farrah·2004·PLoS Medicine
DOI 10.1371/journal.pmed.0010008PMC PMC523885
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Chronic obstructive pulmonary disease and emphysema are a frequent result of long-term smoking, but the exact mechanisms, specifically which types of cells are associated with the lung destruction, are unclear. METHODS AND FINDINGS: We studied different subsets of lymphocytes taken from portions of human lungs removed surgically to find out which lymphocytes were the most frequent, which cell-surface markers these lymphocytes expressed, and whether the lymphocytes secreted any specific factors that could be associated with disease. We found that loss of lung function in patients with chronic obstructive pulmonary disease and emphysema was associated with a high percentage of CD4+ and CD8+ T lymphocytes that expressed chemokine receptors CCR5 and CXCR3 (both markers of T helper 1 cells), but not CCR3 or CCR4 (markers of T helper 2 cells). Lung lymphocytes in patients with chronic obstructive pulmonary disease and emphysema secrete more interferon gamma--often associated with T helper 1 cells--and interferon-inducible protein 10 and monokine induced by interferon, both of which bind to CXCR3 and are involved in attracting T helper 1 cells. In response to interferon-inducible protein 10 and monokine induced by interferon, but not interferon gamma, lung macrophages secreted macrophage metalloelastase (matrix metalloproteinase-12), a potent elastin-degrading enzyme that causes tissue destruction and which has been linked to emphysema. CONCLUSIONS: These data suggest that Th1 lymphoctytes in the lungs of people with smoking-related damage drive progression of emphysema through CXCR3 ligands, interferon-inducible protein 10, and monokine induced by interferon.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.0010008

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Chemokine Receptor Expression on Peripheral Lung Lymphocytes (A) Single color histograms showing expression of chemokine receptors CCR4, CCR5, and CXCR3 from representative control and emphysema participants. (B) Pooled data from all participants (control, n = 10; emphysema, n = 18) showing percent (median ± SD) of total lung lymphocytes expressing CCR4 and CCR5. (C) Pooled data from same participants showing percent (median ± SD) CCR5 expression on CD4 (top) and CD8 (middle) T cells, and CXCR3 expression on unfractionated T cells (bottom) from the same participant groups. (D) Analysis of total lung lymphocyte chemokine receptor (median ± SD) profiles among participants with emphysema. Participants had either (1) lung volume reduction surgery for emphysema (non-cancer, n = 8) or (2) lung resection for treatment of small peripheral cancer (n = 10). Participants showed similar inflammatory indices as determined by CCR5 expression. In (B) and (C), *, p < 0.001; †, p = 0.01; ‡, p = 0.02; ∫, p = 0.007 (Mann-Whitney test) for the comparison of emphysema and control groups.
Figure 1 Chemokine Receptor Expression on Peripheral Lung Lymphocytes (A) Single color histograms showing expression of chemokine receptors CCR4, CCR5, and CXCR3 from representative control and emphysema participants. (B) Pooled data from all participants (control, n = 10; emphysema, n = 18) showing percent (median ± SD) of total lung lymphocytes expressing CCR4 and CCR5. (C) Pooled data from same participants showing percent (median ± SD) CCR5 expression on CD4 (top) and CD8 (middle) T cells, and CXCR3 expression on unfractionated T cells (bottom) from the same participant groups. (D) Analysis of total lung lymphocyte chemokine receptor (median ± SD) profiles among participants with emphysema. Participants had either (1) lung volume reduction surgery for emphysema (non-cancer, n = 8) or (2) lung resection for treatment of small peripheral cancer (n = 10). Participants showed similar inflammatory indices as determined by CCR5 expression. In (B) and (C), *, p < 0.001; †, p = 0.01; ‡, p = 0.02; ∫, p = 0.007 (Mann-Whitney test) for the comparison of emphysema and control groups.CC BY · PubMed Central
Figure 2 Expression of CXCR3 in Lungs of Control and Emphysematous Smoker Individuals (A) Representative forward and side-scatter characteristics of whole lung cells from a participant with COPD and emphysema. Anti-CD11b PE-conjugated and anti-CD14 FITC-conjugated antibodies detect lung macrophages (middle), and histogram of mean fluorescence intensity showing anti-CXCR3-Cy5 and control antibodies (cIg) detects lung macrophages in the patient with emphysema. (B) Pooled data from control individuals without (n = 5) and with (n = 8) emphysema. Columns are median, bars represent SD. *, p = 0.009 (Mann-Whitney test) for the comparison of emphysema and control participants. (C) Negative association between CXCR3 expression on CD3+ T cells and FEV1 percentage predicted based on an R2 goodness-of-fit statistic of 0.27 (p = 0.0089, r = −0.52, n = 24).
Figure 2 Expression of CXCR3 in Lungs of Control and Emphysematous Smoker Individuals (A) Representative forward and side-scatter characteristics of whole lung cells from a participant with COPD and emphysema. Anti-CD11b PE-conjugated and anti-CD14 FITC-conjugated antibodies detect lung macrophages (middle), and histogram of mean fluorescence intensity showing anti-CXCR3-Cy5 and control antibodies (cIg) detects lung macrophages in the patient with emphysema. (B) Pooled data from control individuals without (n = 5) and with (n = 8) emphysema. Columns are median, bars represent SD. *, p = 0.009 (Mann-Whitney test) for the comparison of emphysema and control participants. (C) Negative association between CXCR3 expression on CD3+ T cells and FEV1 percentage predicted based on an R2 goodness-of-fit statistic of 0.27 (p = 0.0089, r = −0.52, n = 24).CC BY · PubMed Central
Figure 3 IFN-γ, MIG, and IP-10 Production by Isolated Lung Lymphocytes (A–C) Lung lymphocytes from control individuals and participants with emphysema were cultured without additional stimulation for 3 or 4 d and assessed for secretion of (A) IFN-γ, (B) MIG, and (C) IP-10 (control, n = 8; emphysema, n = 12). Columns are median, bars represent SD. *, p= 0.007; †, p = 0.01; ‡, p = 0.02 for the comparison of emphysema and control participants. (D) The same cells from a representative ex-smoker individual with emphysema were either left unstimulated (No ST) or treated with PMA/ionomycin (PMA/I) for 24 h and assessed for surface CD8 and CD69 expression and the intracytoplasmic accumulation of IFN-γ by flow cytometry. (E) Production of IL-4 by lung lymphocytes. Lung lymphocytes from a representative ex-smoker individual with emphysema were cultured for 24 h with or without PMA/ionomycin stimulation (PMA/I) and assessed for intracytoplasmic IL-4 and IFN-γ accumulation by flow cytometry.
Figure 3 IFN-γ, MIG, and IP-10 Production by Isolated Lung Lymphocytes (A–C) Lung lymphocytes from control individuals and participants with emphysema were cultured without additional stimulation for 3 or 4 d and assessed for secretion of (A) IFN-γ, (B) MIG, and (C) IP-10 (control, n = 8; emphysema, n = 12). Columns are median, bars represent SD. *, p= 0.007; †, p = 0.01; ‡, p = 0.02 for the comparison of emphysema and control participants. (D) The same cells from a representative ex-smoker individual with emphysema were either left unstimulated (No ST) or treated with PMA/ionomycin (PMA/I) for 24 h and assessed for surface CD8 and CD69 expression and the intracytoplasmic accumulation of IFN-γ by flow cytometry. (E) Production of IL-4 by lung lymphocytes. Lung lymphocytes from a representative ex-smoker individual with emphysema were cultured for 24 h with or without PMA/ionomycin stimulation (PMA/I) and assessed for intracytoplasmic IL-4 and IFN-γ accumulation by flow cytometry.CC BY · PubMed Central
Figure 4 Regulation of MMP12 by Type 1 Cytokines (A) CD14+, lymphocyte-depleted lung leukocytes were cultured with and without the indicated amounts of recombinant human IP-10 and IFN-γ, and supernatants were assessed for the presence of MMP12 by Western blotting. (B) Fold increase relative to unstimulated of MMP12 mRNA from lung macrophages stimulated without (–) and with (+) 500 ng/ml of IP-10 in the presence or absence of a function-blocking antibody to CXCR3 as determined by real-time PCR. (C and D) Lung tissue from a participant with emphysema (C) shows strong immune staining for MMP12 localized to macrophages (arrows), and (D) shows lung tissue from a control participant without emphysema and with undetectable MMP12. The insets show a high-power view of lung macrophages staining positive (C) and negative (D) for MMP12 (×60) *, p = 0.04.
Figure 4 Regulation of MMP12 by Type 1 Cytokines (A) CD14+, lymphocyte-depleted lung leukocytes were cultured with and without the indicated amounts of recombinant human IP-10 and IFN-γ, and supernatants were assessed for the presence of MMP12 by Western blotting. (B) Fold increase relative to unstimulated of MMP12 mRNA from lung macrophages stimulated without (–) and with (+) 500 ng/ml of IP-10 in the presence or absence of a function-blocking antibody to CXCR3 as determined by real-time PCR. (C and D) Lung tissue from a participant with emphysema (C) shows strong immune staining for MMP12 localized to macrophages (arrows), and (D) shows lung tissue from a control participant without emphysema and with undetectable MMP12. The insets show a high-power view of lung macrophages staining positive (C) and negative (D) for MMP12 (×60) *, p = 0.04.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Research works printed but not linked: 3

  1. Kay, 1997, Ciba Found Symp, 206, 56
  2. Anthonisen, 1994, JAMA, 272, 1497, 10.1001/jama.1994.03520190043033 · DOI
  3. Fiocchi, 1985, Acta Chir Scand Suppl, 525, 11

Cited by

Sorted by citations

See all 484

Related

Metadata

Authors
Grumelli, S., Corry, D. B., Song, L.-Z., Song, L., Green, L., Huh, J., Hacken, J., Espada, R., Bag, R., Lewis, D. E., & Kheradmand, F.
Affiliations
  • Baylor College of Medicine (US)
  • Michael E. DeBakey VA Medical Center (US)
Corresponding author
Kheradmand, Farrah
ORCID
Venue
PLoS Medicine
Publisher
Public Library of Science (PLoS)
Published
2004-10-19
Volume
1
Issue
1
Pages
e8
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
DOI
10.1371/journal.pmed.0010008
PMC
PMC523885
OpenAlex
W2108679807
Cited by
484
References
59
Citations by year
2026: 6 · 2025: 12 · 2024: 21 · 2023: 12 · 2022: 11 · 2021: 21 · 2020: 14 · 2019: 22 · 2018: 16 · 2017: 25 · 2016: 21 · 2015: 28 · 2014: 15 · 2013: 29 · 2012: 31
FWCI
19.11
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Public Health Service (69585, 64061, 72419)
  • National Institute of Allergy and Infectious Diseases (P30AI036211, AI 36211)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords
chronic obstructive pulmonary disease, emphysema, Th1 cells, CXCR3, CCR5, interferon-gamma, CXCL10, macrophage metalloelastase, matrix metalloproteinase-12, elastin degradation, smoking, lung lymphocytes, chemokine receptors
MeSH terms
Aged, Female, Humans, Male, Middle Aged, Pulmonary Emphysema, Smoking, Tomography, X-Ray Computed, Lymphocyte Subsets, Cytokines, Macrophages, Alveolar, Th1 Cells, Disease Progression, Receptors, Chemokine, Chemokines, CXC, Pulmonary Disease, Chronic Obstructive, Chemokine CXCL10, Receptors, CXCR3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review